SCHEMBL29774541

SCHEMBL29774541

CC(C)(C)OC(=O)N1C(=O)c2cccc3c(O)ccc1c23

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 8/20 0.46
▸ ALDH1A1 P00352 3/20 0.43
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ USP2 O75604 3/20 0.42
▸ BLM P54132 1/20 0.42
▸ BCHE P06276 1/20 0.42
▸ GFER P55789 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ RGS12 O14924 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ RORC P51449 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22550209 1.00 BRD4 (0.46) BRD4ALDH1A1MEN1KMT2AUSP2
SCHEMBL22533232 0.79 KMT2A (0.51) BRD4ALDH1A1MEN1KMT2AUSP2
SCHEMBL5121655 0.75 BCHE (0.54) ALDH1A1BCHE
SCHEMBL9290413 0.74 PKM (0.57) BRD4ALDH1A1MEN1KMT2AUSP2
SCHEMBL24317753 0.73 CYP1B1 (0.48) BRD4ALDH1A1MEN1KMT2ABCHE
SCHEMBL22550208 0.72 HDAC6 (0.41) BRD4ALDH1A1MEN1KMT2ALMNA
SCHEMBL13144372 0.72 CES1 (0.61) ALDH1A1MEN1KMT2ABCHEMAPT
SCHEMBL24317752 0.71 CYP1B1 (0.48) ALDH1A1MEN1KMT2ABCHEMAPT
SCHEMBL9290404 0.70 PKM (0.50) BRD4ALDH1A1MEN1KMT2AUSP2
SCHEMBL31015698 0.70 IDO1 (0.34) BRD4BCHERORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS C4 THERAPEUTICS, INC. (US) 2023-03-16 — — US disclosed
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos C4 THERAPEUTICS, INC. (US) 2022-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407732-B1 Tricyclic degraders of Ikaros and Aiolos CRBN, IKZF1, IKZF3 BRD4 252/4885ALDH1A1 3827/4885MEN1 2242/4885
US-20230082430-A1 TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS CRBN, IKZF1, IKZF3 BRD4 252/4885ALDH1A1 3827/4885MEN1 2242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback